Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of ...

Pharming Group (NASDAQ:PHAR – Get Free Report) had its price target hoisted by research analysts at Oppenheimer from $30.00 ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...

Across the recent three months, 4 analysts have shared their insights on Pharming PHAR, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Discover key insights from Pharming Group's Q4 2024 earnings call. Explore strong revenue growth, RUCONEST & Joenja drivers, and 2025 strategic priorities.

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...